These are the stocks posting the largest moves after the bell on Monday: Biogen, Walt Disney Company and more.
After a five-month search, Biogen names Michel Vounatsos its next CEO. CNBC's Meg Tirrell reports.
CNBC's Meg Tirrell reports on the more optimistic Alzheimer's drug trials from Biogen after the disappointing news about Eli Lilly's trial for their version of a drug.
CNBC's Jim Cramer explains why he is watching Biogen and Apple.
Some of the names on the move ahead of the open.
Beaten-up biotech stocks could fall further, according to one technical analyst who sees trouble in the charts.
Health-care stocks haven't gotten the green light many expected from Hillary Clinton's election loss.
The "Fast Money" traders weigh in on Eli Lilly and Juno Therapeutics, following failed drug trials.
Solanezumab, an experimental drug from Eli Lilly, failed to slow the loss of cognitive ability in patients with mild Alzheimer's disease.
Ronny Gal, Bernstein senior analyst, weighs in on Eli Lilly's failed Alzheimer's drug study results.
CNBC's Dominic Chu takes a look at some of the large cap S&P 500's biggest losers so far in 2016.
The “Fast Money Halftime Report” traders weigh in on the biotech sector, with Eli Lilly and Juno Therapeutics stocks dropping significantly.
Boris Schlossberg, Managing Director of FX Strategy, BK Asset Management, and Ari Wald, Oppenheimer, look at the post-election market surge.
U.S. stock closed mostly lower on Wednesday as earnings season continued, while solid economic data helped financials.
U.S. stock index futures pointed to a solidly lower open, as investors got ready to wade through another downpour of earnings.
Jefferies shares its favorite biotech stock ideas to pick up amid the recent share price weakness due to Hillary Clinton's rising poll numbers.
A new drug being tested slows Alzheimer's by removing plaque buildup in the brain. It's hope for millions suffering from the disease.
U.S. stocks steadied Wednesday, closing narrowly mixed after the Fed minutes affirmed previous expectations for a possible December rate hike.
Chris Raymond, Raymond James analyst, discusses how to trade the biotech sell-off amid election season.
CNBC took a deep look at stocks in one urban area that have produced big stock returns in a wide diversity of industries.